Cargando…

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibroti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, Sandra, Ortiz, Cristina, Bachtler, Nadine, Gu, Wenyi, Grünewald, Leon D., Kraus, Nico, Schierwagen, Robert, Hieber, Christoph, Meier, Caroline, Tyc, Olaf, Joseph Brol, Maximilian, Uschner, Frank Erhard, Nijmeijer, Bart, Welsch, Christoph, Berres, Marie‐Luise, Garcia‐Ruiz, Carmen, Fernandez‐Checa, Jose Carlos, Trautwein, Christian, Vogl, Thomas J., Zeuzem, Stefan, Trebicka, Jonel, Klein, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Liver Failure/Cirrhosis/Portal Hypertension
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026969/ https://www.ncbi.nlm.nih.gov/pubmed/35993369 http://dx.doi.org/10.1002/hep.32746

Ejemplares similares

Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis
por: Arabi, Yaseen M, et al.
Publicado: (2012)

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
por: Rockey, Don C, et al.
Publicado: (2014)

Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease
por: Hadjihambi, Anna, et al.
Publicado: (2017)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

SARC‐F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension
por: Leeming, D J, et al.
Publicado: (2013)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver
por: Schmid, Christian David, et al.
Publicado: (2023)

Diagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injury
por: Gambino, Carmine, et al.
Publicado: (2023)

CD11b(+)CD43(hi)Ly6C(lo) splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis
por: Zhang, Shaoying, et al.
Publicado: (2023)

Xenogeneic cross-circulation for physiological support and recovery of ex vivo human livers
por: Wu, Wei Kelly, et al.
Publicado: (2023)

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study
por: Shan, Jingxuan, et al.
Publicado: (2023)

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
por: Madsen, Bjørn S., et al.
Publicado: (2020)

Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients
por: Ohfuji, Satoko, et al.
Publicado: (2014)

PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis
por: Burza, Maria Antonella, et al.
Publicado: (2014)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Bacterascites: A study of clinical features, microbiological findings, and clinical significance
por: Oey, Rosalie C., et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells
por: Bachtler, Nadine, et al.
Publicado: (2023)

Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump
por: Stirnimann, Guido, et al.
Publicado: (2022)

Neonates with acute liver failure have higher overall mortality but similar posttransplant outcomes as older infants
por: Antala, Swati, et al.
Publicado: (2023)

Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation
por: Raza, Muhammad H., et al.
Publicado: (2023)

Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
por: Slack, A J, et al.
Publicado: (2013)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience
por: Verma, Anita, et al.
Publicado: (2020)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study
por: Yin, Dalong, et al.
Publicado: (2020)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study
por: Gitto, Stefano, et al.
Publicado: (2022)

Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease
por: Siddiqui, Mohammad S., et al.
Publicado: (2022)

A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS ‐ Modified TIPS Score
por: Fürschuß, Luisa, et al.
Publicado: (2022)

An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection
por: Ruan, Dongsheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uloqfrdagmpke2cdrev8bg7n68